Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX22 + Trastuzumab + Chemotherapy in 1L HER2+ Metastatic Pancreatic Cancer
NCT07176702Phase 2Active, not recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of hlx22 in pancreatic ductal adenocarcinoma (PDAC), sponsored by Zhongshan Hospital, Fudan University. Started Sep 2025; status: active, not recruiting.
02
Drugs
hlx22
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07176702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07176702.